TruScreen Investor Briefing
Company Announcement 07 March, 2017
TruScreen Investor Briefing
Cervical cancer technology company, TruScreen Limited (NZAX:TRU), advises that it wishes to
provide to shareholders a copy of its latest investor briefing presentation.
Please find attached a copy of the presentation, or you may download a copy at
http://truscreen.com/investor-centre/reports-presentations/.
ENDS
For more information visit www.truscreen.com
Contact:
Martin Dillon, TruScreen Chief Executive Officer
email: martindillon@truscreen.com
About TruScreen:
TruScreen real time cervical cancer technology utilises a digital wand which is placed on the surface
of the cervix to measure electrical and optical signals from the surrounding tissue to identify
precancerous change, or cervical intraepithelial neoplasia (CIN).TruScreen has distribution contracts
in a range of international markets, including China, Latin America, Central Asia, Russia, the Middle
East and Eastern Europe.
-ENDS-
---
Presentation March 2017
The information in this presentation dated March 2017 is a snapshot and does not contain ALL information necessary to make an investment
decision.It DOES NOT PUPORT TO BE A COMPLETE DESCRIPTION OF TRUSCREEN. THIS PRESENTATION IS NOT INVESTMENT ADVICE OR FINANCIAL
ADVICE. IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF TRUSCREEN, INCLUDING THE MERITS AND
RISKS INVOLVED. INVESTORS SHOULD CONSULT WITH THEIR OWN LEGAL, TAX, BUSINESS AND/OR FINANCIAL ADVISORS.
THE INFORMATION CONTAINED IN THIS PRESENTATION HAS BEEN PREPARED IN GOOD FAITH BY TRUSCREEN. There can be no assurance that actual
outcomes will not materially differ from the forward looking statements presented. A number of important factors could cause actual results or
performance to differ materially from the forward-looking statements. The forward-looking statements are based on information available to
TruScreen as at the date of this presentation. TruScreen, its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and
agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this
presentation. Except as required by law (including the NZAX Listing Rules), TruScreen undertakes no obligation to provide anyadditional or updated
information whether as a result of new information, future events or results or otherwise.
TO THE MAXIMUM EXTENT PERMITTED BY LAW, TRUSCREEN, ITS DIRECTORS, OFFICERS, EMPLOYEES AND AGENTS DISCLAIM ALL LIABILITY AND
RESPONSIBILITY (INCLUDING WITHOUT LIMITATION ANY LIABILITY ARISING FROM FAULT OR NEGLIGENCE ON THE PART OF TRUSCREEN, ITS
DIRECTORS, OFFICERS, EMPLOYEES AND AGENTS) FOR ANY DIRECT OR INDIRECT LOSS OR DAMAGE WHICH MAY BE SUFFERED BY ANY RECIPIENT
THROUGH USE OF OR RELIANCE ON ANYTHING CONTAINED IN, OR OMITTED FROM, THIS PRESENTATION.
This presentation is not a prospectus, investment statement or disclosure document, or an offer of shares for subscription, or sale, in any jurisdiction
•
•
•
•
•
•
•
•
•
•
o
o
o
o
•
1. CHINA
•
•
•
•
•
•
2. MEXICO
•
•
•
•
3. EUROPE
•
•
•
•
4. INDIA
•
•
•
•
•
•
Mexico:
o
o
o
China:
o
o
o
o
Europe:
o
o
India:
o
o
o
•
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- PEB — Pacific Edge Limited: Pacific Edge Undertakes $8m Share Placement2017-02-14
“Company Announcement 15 th February 2017 “We believe our existing infrastructure and resources are appropriate for our medium term growth goals and anticipate capital requirements for our growth strategy in FY17 will be at a similar level to FY16. The additional funds will b…”
- PEB — Pacific Edge Limited: Cxb Monitor significantly outperforms FDA approved tests2017-03-05
“Company Announcement 6 March 2017 “Cxbladder Monitor provides an opportunity to enhance the standard of care for bladder cancer patients, making surveillance of patients with this disease and the monitoring for the recurrence of the disease, more effective a…”
- BAI — Being AI: Market Update and Director Resignation2017-02-27
“7322851_1 TRS INVESTMENTS LTD Correspondence: Registered Office: PO Box 26448 Level 2 Epsom Tower Building Auckland 1344 50 Customhouse Quay Wellington TRS: Market Update and Director Resignation Following completion…”